#

## CDC73 (D38E12) Rabbit mAb 9218



Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	<b>Reactivity:</b> H R Mk	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 60	<b>Source/Isotype:</b> Rabbit IgG	UniProt ID: #Q6P1J9	Entrez-Gene Id: 79577		
Product Usage Information		<b>Application</b> Western Blotting Immunoprecipitation			<b>Dilution</b> 1:1000 1:200			
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.						
Specificity/Sen	sitivity	CDC73 (D38E12) Rabbit mAb recognizes endogenous levels of total CDC73 protein.						
Species predict based on 100% homology	ted to react sequence	Mouse						
Source / Purifi	cation	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg407 of human CDC73 protein.						
Background		CDC73 (HPRT2) is a putative tumor suppressor protein thought to bind RNA polymerase II to help inhibit cell cycle progression (1,2). Commonly referred to as parafibromin, CDC73 is expressed in endocrine tissues, kidney, heart, and skeletal muscle and is localized to both nuclear and cytoplasmic compartments (3). CDC73 acts as a Wnt signaling regulator as it binds the carboxy-terminal region of $\beta$ - catenin (4). Mutations in the corresponding gene cause an endocrine disorder known as hyperparathyroidism 2, which is characterized by hypercalcemia, bone resorption, and the development of jaw tumors (5).						
Background Re	eferences	1. Rozenblatt-Rosen, O 2. Shi, X. et al. (1997) <i>N</i> 3. Woodard, G.E. et al. 4. Mosimann, C. et al. (20 5. Bradley, K.J. et al. (20	<i>1ol Cell Biol</i> 17, 116 (2005) <i>Oncogene</i> 2 (2006) <i>Cell</i> 125, 327	0-9. 4, 1272-6. '-41.				
Species Reactiv	vity	Species reactivity is de	termined by testing	g in at least one approve	ed application (e.g.,	western blot).		
Western Blot B	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications K	ey	W: Western Blotting IP: Immunoprecipitation						
Cross-Reactivit	ty Key	H: Human R: Rat Mk: Monkey						
Trademarks ar	nd Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.						
		All other trademarks a more information.	re the property of	heir respective owners.	Visit cellsignal.com	/trademarks for		
Limited Uses		the following terms ap terms and conditions t	ply to Products pro hat are in addition	a writing signed by a leg wided by CST, its affiliat to, or different from, th / authorized representa	es or its distributors ose contained here	s. Any Customer's in, unless		
		approved, cleared, or l	icensed by the FDA	se Only or a similar labe or other regulatory for duct for any diagnostic o	eign or domestic en	itity, for any		

any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products on services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.